Bard Davol

Bard Davol, headquartered in Warwick, Rhode Island, is a subsidiary of C.R. Bard, Inc. Established in 1874, the company boasts a rich history spanning over 140 years. Today, Bard Davol employs 156 individuals and generates approximately $500 million in annual revenue. Bard Davol specializes in providing innovative solutions for soft tissue reconstruction. Their extensive portfolio encompasses products for hernia repair, specialized surgical procedures, fixation, and biologic implants. Their offerings include mesh prosthetics, biologic implants, surgical instruments, and techniques for various hernia repair procedures, along with products for autotransfusion, hemostasis, laparoscopy, hysteroscopy, pulsed lavage, and wound management. The company distinguishes itself through a commitment to research and development, constantly expanding its product line to meet evolving clinical needs. Bard Davol's focus on reliability, innovation, and exceptional value has earned them a reputation for providing solutions that meet the highest standards. For further information, please visit davol.com.